Sagimet Biosciences Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
SGMT$10.89+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity (unaudited)
CONDENSED STATEMENTSOF STOCKHOLDERS’ EQUITY
(in thousands, except share amounts)
| Series ACommon Stock · Series BCommon Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | (loss) Income | Equity | |
| Balance at January 1, 2026 | 31,954,105 | $3 | 567,494 | $— | $457,607 | $(346,349) | $120 | $111,381 |
| Issuance of Series A common stock for vesting of restricted stock units | 63,508 | — | — | — | — | — | — | — |
| Stock-based compensation expense | — | — | — | — | 1,839 | — | — | 1,839 |
| Unrealized loss on marketable securities | — | — | — | — | — | — | (112) | (112) |
| Net loss | — | — | — | — | — | (10,650) | — | (10,650) |
| Balance at March 31, 2026 | 32,017,613 | $3 | 567,494 | $— | $459,446 | $(356,999) | $8 | $102,458 |
| Sale of Series A common stock, net of issuance costs of $11,145 | 29,166,700 | 3 | — | — | 163,852 | — | — | 163,855 |
| Issuance of Series A common stock upon exercise of stock options | 15,056 | — | — | — | 96 | — | — | 96 |
| Issuance of Series A common stock for purchases under employee stock purchase plan | 16,071 | — | — | — | 93 | — | — | 93 |
| Stock-based compensation expense | — | — | — | — | 3,691 | — | — | 3,691 |
| Unrealized loss on marketable securities | — | — | — | — | — | — | (85) | (85) |
| Net loss | — | — | — | — | — | (13,953) | — | (13,953) |
| Balance at June 30, 2026 | 61,215,440 | $6 | 567,494 | $— | $627,178 | $(370,952) | $(77) | $256,155 |
| Series ACommon Stock · Series BCommon Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Deficit | Income | Equity | |
| Balance at January 1, 2025 | 30,674,855 | $3 | 1,520,490 | $— | $450,883 | $(295,311) | $230 | $155,805 |
| Stock-based compensation expense | — | — | — | — | 1,472 | — | — | 1,472 |
| Unrealized loss on marketable securities | — | — | — | — | — | — | (109) | (109) |
| Net loss | — | — | — | — | — | (18,176) | — | (18,176) |
| Balance at March 31, 2025 | 30,674,855 | $3 | 1,520,490 | $— | $452,355 | $(313,487) | $121 | $138,992 |
| Issuance of Series A common stock upon exercise of stock options | 99 | — | — | — | 1 | — | — | 1 |
| Stock-based compensation expense | — | — | — | — | 1,598 | — | — | 1,598 |
| Unrealized loss on marketable securities | — | — | — | — | — | — | (45) | (45) |
| Net loss | — | — | — | — | — | (10,386) | — | (10,386) |
| Balance at June 30, 2025 | 30,674,954 | $3 | 1,520,490 | $— | $453,954 | $(323,873) | $76 | $130,160 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.